Jack Harley, Therapeutic Neuroscience at Oxford University
reviewed by Dr Michael Yapko
Tuesday, February 18, 2020
Jack Harley, Therapeutic Neuroscience at Oxford University
Tuesday, February 18, 2020

Post-infectious IBS: What You Need to Know

Contents

While most people make a full recovery after suffering from an intestinal illness, like acute gastroenteritis, some people go on to develop continued gut discomfort or even IBS. So, what do you need to know about this kind of IBS, what symptoms do people with post-infectious IBS (PI-IBS) experience, and who is more likely to develop this condition after an infection? Read on to learn more about post-infectious IBS and learn about common treatments.

Irritable Bowel Syndrome vs. Post-infectious IBS (PI-IBS)

Irritable bowel syndrome (IBS) is a common digestive disorder that affects 1 in 10 people worldwide. For most people with IBS, the cause is unknown, although factors such as existing psychiatric conditions and previous gastrointestinal infection are thought to play a role. 

While most people with a stomach or intestinal infection fully recover after the illness, some may experience IBS symptoms on a longer-term basis. If symptoms of IBS begin following a gastrointestinal infection, it is called post-infectious IBS (PI-IBS).

As we dive into our exploration of PI-IBS, it is worth noting that there is still much science doesn't understand about PI-IBS. We've used the best research available for this article, but more studies are needed to give us a better understanding of this condition and make it possible to create better therapies that treat multiple symptoms of PI-IBS. 

What is post-infectious IBS (PI-IBS)?

Post-infectious IBS (PI-IBS) is a type of IBS that is caused by a viral infection (e.g., Norovirus), a bacterial infection (e.g., Campylobacter jejuni)or a parasitic infection (e.g., giardia) of the gastrointestinal tract. PI-IBS is estimated to makes up between 5% and 30% of all IBS cases. In PI-IBS, abdominal pain symptoms and changes in bowel habits can persist after the infection has resolved.

PI-IBS usually begins following intestinal enteritis (inflammation of the intestines) or gastroenteritis (stomach infection). These infections are usually caused by eating or drinking foods contaminated with bacteria, viruses, or parasites—known as food poisoning. Approximately one-third of people who have a digestive tract infection will go on to develop PI-IBS.

While the impact of intestinal enteritis can be severe, symptoms usually last less than five days. However, symptoms related to PI-IBS may last for many months or even years.  Intestinal enteritis is more common in certain groups of people, including those: 

  • From Western countries visiting developing nations 
  • Undergoing radiography (X-rays)
  • With pre-existing conditions such as Crohn's disease or ulcerative colitis
PI-IBS facts

What are the symptoms of PI-IBS?

The symptoms of PI-IBS are similar to typical IBS and include: 

  • Abdominal pain
  • Diarrhea and constipation (diarrhea is more common)
  • Bloating and gas
  • Feelings of urgency to go to the toilet
  • Feelings of incomplete evacuation
  • Mucus in stools

The majority of people with PI-IBS have an increased perception of visceral pain compared to the more 'standard' forms of IBS. This may highlight long-term changes in pain processing in people who have PI-IBS. 

Diarrhea or mixed bowel habits are also generally more common than constipation in PI-IBS. These symptoms resemble those seen in a subtype of IBS known as diarrhea-predominant IBS (IBS-D).

How is PI-IBS diagnosed?

There are currently no objective medical tests for IBS or PI-IBS, and the syndrome is diagnosed based on symptoms. The ROME IV criteria for IBS required for a diagnosis is recurrent abdominal pain for at least one day per week for the last three months that is associated with two or more of the following: 

  • Related to defecation
  • Associated with a change in stool frequency
  • Associated with a change in stool appearance

It is important to note that IBS symptoms can mask other diseases, such as celiac disease and inflammatory bowel disease. Therefore, additional screening tests to rule out these conditions may be advised by your doctor, including blood tests and stool tests. 

What causes PI-IBS?

Research has shown that protozoan and parasitic infections are most likely to cause PI-IBS, with more than 40% of these infections resulting in PI-IBS. This was followed by bacterial infections, of which 14% resulted in PI-IBS

A range of bacterial strains such as Campylobacter, Salmonella, and Shigella have been shown to cause symptoms of PI-IBS. These strains can be spread by contaminated food or water, or contact with people or animals who have the virus. The most common bacterial species to cause PI-IBS following a stomach infection is Campylobacter jejuni. 

How does PI-IBS begin?

The precise link between infection of the gastrointestinal tract and PI-IBS is unknown, but several theories have been put forward.

The first is that changes in immune function causes PI-IBS. The body fights infection by initiating inflammation, which is part of the immune response. But the immune system needs to turn on and off at the right times to fight the infection without causing other problems. It is thought that a delay in turning off the immune system may lead to low-grade inflammation that may persist for years and may contribute to PI-IBS. 

Another possible cause of PI-IBS are changes to the nerves involved in digestion following infection. An infection may cause nerves in the gut responsible for sensation and motility (speed of transit of fecal material food along the GI tract) to become more sensitive than usual. This can result in altered bowel movements such as constipation or diarrhea and abdominal pain—both symptoms of PI-IBS. 

Various other features have been identified as potentially contributing to the onset of PI-IBS, including changes in the bacteria in the gut, presence of certain toxins (antigens) in food, and altered permeability of the intestines.

Risk factors for PI-IBS

PI-IBS is more common in women and individuals who report chronic stress or anxiety. Additionally, adverse life events in the months before infection increase the risk by about two-fold. 

Research has shown those of younger ages (between 19-29 years) had three times higher risk of developing PI-IBS than those over the age of 60. Interestingly, those who reported vomiting during the infection reduced the risk of PI-IBS by around half. 

Additionally, there are other factors that are associated with an increased risk of developing PI-IBS, including:

  • The severity and duration of the stomach infection
  • Psychological distress associated with an intestinal infection
  • Using antibiotics to treat intestinal enteritis

Get access to our free mini-course for IBS

I want the mini course
Learn how to self-manage IBS
Gut-brain, science & tools
Sent direct to your email

Take control of how you think, feel & act with Mindset

Try for free
Self-guided hypnosis app
Developed by world-experts
Courses on anxiety, negative thinking, achieving goals & more

Get early access to our hot flashes program

Learn more
Hypnosis-based guided imagery
Menopause education
Symptom tracking & more!

Treatments for PI-IBS

Just as with IBS, there is currently no cure for PI-IBS. Treatment is much the same as other types of IBS and involves reducing the severity of symptoms and avoiding triggers. Options include the use of medicines, dietary changes, and psychological therapies like gut-directed hypnotherapy. 

Medications for PI-IBS

Your doctor may prescribe antibiotics such as rifaximin (Xifaxan) to treat the initial stomach or intestinal infection. However, it is worth noting that antibiotics have been shown to increase the risk of developing PI-IBS following a gastrointestinal infection. 

If diarrhea is a symptom in PI-IBS, you may be prescribed anti-diarrheal medicines such as loperamide (Imodium). Additionally, tricyclic antidepressants such as amitriptyline may be prescribed in small doses to treat IBS symptoms. This type of antidepressant may be effective in diarrhea-predominant IBS (IBS-D) as it helps to slow bowel movements. 

A non-prescription medication option is probiotics, which help to boost 'friendly' bacteria in the digestive tract. There is some evidence that probiotics help to reduce symptoms of IBS. 

Dietary changes

Some people will manage their IBS symptoms by trying various dietary interventions, such as the popular low FODMAP diet. The low FODMAP diet removes lactose, and other compounds known to commonly trigger IBS symptoms (fructans, disaccharides, monosaccharides, and polyols). Several studies have shown that the low FODMAP diet is effective in reducing symptoms of IBS such as bloating, abdominal pain, and diarrhea. 

Psychological treatments

Since psychological factors are important to PI-IBS, these should be formally assessed and treated. High levels of anxiety and depression may make it harder to recover, and these psychological issues will usually need to be addressed to make a full recovery. 

Stress-reduction and psychological therapy techniques may help to restore the connection between the brain and the gut and reduce symptoms in PI-IBS. These interventions include gut-directed hypnotherapy, mindfulness meditation, yoga, and cognitive behavioral therapy (CBT). 

Prognosis

PI-IBS can last up to several months or even years. Studies suggest that up to 50% of patients with PI-IBS will recover without any specific treatment within 8 years. 

Can COVID-19 cause IBS?

Research is still evolving, and it is too early to say whether the virus responsible for COVID-19, Sars-CoV-2, can cause PI-IBS. Up to 40% of COVID-19 patients experience gastrointestinal symptoms. The most common gastrointestinal symptoms of COVID-19 are diarrhea, nausea, loss of appetite, vomiting, abdominal pain, and heartburn. 

Considering that post-infectious IBS can be caused by a viral infection of the digestive tract, and that SARS-CoV-2 can enter the body through the digestive tract, there is some reason to believe that this new coronavirus can cause PI-IBS. 

The Wrap-Up

Post-infectious IBS refers to IBS symptoms that arise following an infection of the digestive tract. This condition is usually caused by bacterial or parasitic infections rather than a viral infection. Most cases of PI-IBS cause diarrhea-predominant IBS (IBS-D) rather than constipation-predominant IBS (IBS-C). Several treatment options are available to reduce symptoms, however, more research into this condition is needed.

Self-hypnosis app for sleep, anxiety & depression

Try the Mindset app
Self-guided hypnosis app
Developed by world-experts
Courses on anxiety, negative thinking, achieving goals & more

Want our free IBS mini-course?

Get free IBS course
Self-manage IBS symptoms
Gut-brain axis, science & tools
Sent direct to your email

Manage hot flashes naturally, at home

Get Early Access
Hypnosis-based guided imagery
Menopause education
Symptom tracking & more!

Our Sources

Mindset Health only uses high-quality sources, including peer-reviewed research, to support our articles. We work with experts to ensure our content is helpful, accurate and trustworthy.

  1. Oka, P., Parr, H., Barberio, B., Black, C.J., Savarino, E.V. and Ford, A.C., 2020. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5(10), pp.908-917. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30217-X/fulltext
  2. 2.       Mykletun, A., Jacka, F., Williams, L., Pasco, J., Henry, M., Nicholson, G.C., Kotowicz, M.A. and Berk, M., 2010. Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women. BMC gastroenterology, 10(1), pp.1-9. https://link.springer.com/article/10.1186/1471-230X-10-88
  3. 3.       Persson, R., Wensaas, K.A., Hanevik, K., Eide, G.E., Langeland, N. and Rortveit, G., 2015. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC gastroenterology, 15(1), pp.1-7. https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-015-0296-0
  4. 4.       Thabane, M. and Marshall, J.K., 2009. Post-infectious irritable bowel syndrome. World journal of gastroenterology: WJG, 15(29), p.3591. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2721231/
  5. 5.       Iacob, T., Ţăţulescu, D.F. and Dumitraşcu, D.L., 2017. Therapy of the postinfectious irritable bowel syndrome: an update. Clujul Medical, 90(2), p.133. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433563/
  6. 6.       Neal, K.R., Barker, L. and Spiller, R.C., 2002. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut, 51(3), pp.410-413. https://gut.bmj.com/content/51/3/410.short
  7. 7.       Theis, V.S., Sripadam, R., Ramani, V. and Lal, S., 2010. Chronic radiation enteritis. Clinical Oncology, 22(1), pp.70-83. https://www.sciencedirect.com/science/article/pii/S0936655509003306
  8. 8.       Farzaei, M.H., Bahramsoltani, R., Abdollahi, M. and Rahimi, R., 2016. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. Journal of Neurogastroenterology and Motility, 22(4), p.558. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056566/
  9. 9.       Klem, F., Wadhwa, A., Prokop, L.J., Sundt, W.J., Farrugia, G., Camilleri, M., Singh, S. and Grover, M., 2017. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology, 152(5), pp.1042-1054. https://academic.oup.com/cid/article/41/Supplement_8/S577/570403?login=true
  10. 10.   Bai, T., Xia, J., Jiang, Y., Cao, H., Zhao, Y., Zhang, L., Wang, H., Song, J. and Hou, X., 2017. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross‐sectional survey. Journal of gastroenterology and hepatology, 32(5), pp.1018-1025. https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13642
  11. 11.   Irvine, A.J., Chey, W.D. and Ford, A.C., 2017. Screening for celiac disease in irritable bowel syndrome: an updated systematic review and meta-analysis. American Journal of Gastroenterology, 112(1), pp.65-76. https://journals.lww.com/ajg/Abstract/2017/01000/Screening_for_Celiac_Disease_in_Irritable_Bowel.17.aspx
  12. 12.   Monashfodmap.com. 2021. Post infectious IBS. [online] Available at: <https://www.monashfodmap.com/blog/post-infectious-ibs/> [Accessed 13 February 2021]. https://www.monashfodmap.com/blog/post-infectious-ibs/
  13. 13.   Schwille‐Kiuntke, J., Enck, P., Zendler, C., Krieg, M., Polster, A.V., Klosterhalfen, S., Autenrieth, I.B., Zipfel, S. and Frick, J.S., 2011. Postinfectious irritable bowel syndrome: follow‐up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterology & Motility, 23(11), pp.e479-e488. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2982.2011.01779.x
  14. 14.   Ringel, Y. and Maharshak, N., 2013. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology, 305(8), pp.G529-G541. https://journals.physiology.org/doi/abs/10.1152/ajpgi.00207.2012
  15. 15.   Coss-Adame, E. and Rao, S.S., 2014. Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. Current gastroenterology reports, 16(4), p.379. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083372/
  16. 16.   Andresen, V., Löwe, B., Broicher, W., Riegel, B., Fraedrich, K., von Wulffen, M., Gappmayer, K., Wegscheider, K., Treszl, A., Rose, M. and Layer, P., 2016. Post-infectious irritable bowel syndrome (PI-IBS) after infection with Shiga-like toxin-producing Escherichia coli (STEC) O104: H4: a cohort study with prospective follow-up. United European gastroenterology journal, 4(1), pp.121-131. https://journals.sagepub.com/doi/abs/10.1177/2050640615581113
  17. 17.   Thabane, M. and Marshall, J.K., 2009. Post-infectious irritable bowel syndrome. World journal of gastroenterology: WJG, 15(29), p.3591. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721231/
  18. 18.   Neal, K.R., Barker, L. and Spiller, R.C., 2002. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut, 51(3), pp.410-413. https://gut.bmj.com/content/51/3/410.short
  19. 19.   Spiller, R. and Garsed, K., 2009. Postinfectious irritable bowel syndrome. Gastroenterology, 136(6), pp.1979-1988. https://www.sciencedirect.com/science/article/abs/pii/S0016508509003618
  20. 20.   IBS, U. and Us, C., 2021. Post-infectious IBS. [online] Aboutibs.org. Available at: <https://www.aboutibs.org/what-is-ibs-sidenav/post-infectious-ibs.html> [Accessed 13 February 2021]. https://www.aboutibs.org/what-is-ibs-sidenav/post-infectious-ibs.html
  21. 21.   Wouters, M.M., Van Wanrooy, S., Nguyen, A., Dooley, J., Aguilera-Lizarraga, J., Van Brabant, W., Garcia-Perez, J.E., Van Oudenhove, L., Van Ranst, M., Verhaegen, J. and Liston, A., 2016. Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Gut, 65(8), pp.1279-1288. https://pubmed.ncbi.nlm.nih.gov/26071133/
  22. 22.   Spiller, R. and Garsed, K., 2009. Postinfectious irritable bowel syndrome. Gastroenterology, 136(6), pp.1979-1988.  https://www.sciencedirect.com/science/article/abs/pii/S0016508509003618
  23. 23.   Vahedi, H., Merat, S., Momtahen, S., Kazzazi, A.S., Ghaffari, N., Olfati, G. and Malekzadeh, R., 2008. Clinical trial: the effect of amitriptyline in patients with diarrhoea‐predominant irritable bowel syndrome. Alimentary pharmacology & therapeutics, 27(8), pp.678-684.  https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2008.03633.x
  24. 24.   Saggioro, A., 2004. Probiotics in the treatment of irritable bowel syndrome. Journal of clinical gastroenterology, 38, pp.S104-S106.  https://journals.lww.com/jcge/Fulltext/2004/07002/Probiotics_in_The_Treatment_of_Irritable_Bowel.14.aspx
  25. 25.   Staudacher, H.M. and Whelan, K., 2017. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut, 66(8), pp.1517-1527. https://gut.bmj.com/content/66/8/1517.abstract
  26. 26.   Allen, A.P., Dinan, T.G., Clarke, G. and Cryan, J.F., 2017. A psychology of the human brain–gut–microbiome axis. Social and Personality Psychology Compass, 11(4), p.e12309. https://onlinelibrary.wiley.com/doi/abs/10.1111/spc3.12309
  27. 27.   Neal, K.R., Barker, L. and Spiller, R.C., 2002. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut, 51(3), pp.410-413. https://gut.bmj.com/content/51/3/410.short
  28. 28.  Villapol, S., 2020. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Translational Research. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438210/

Similar Articles

No items found.

What is Mindset?

We’re glad you asked! Mindset is a hypnotherapy app for mental health & positive thinking.

Personalized to you

Learn coping skills

Evidence-based

Created by experts

Available 24/7

Loved by thousands

Take our free IBS quiz
Start now